Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.45), $0.07 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.62 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.